Literature DB >> 23925681

Agranulocytosis with deferiprone treatment of superficial siderosis.

Nikhil Huprikar1, Marisa Gossweiler, Maureen Callaghan, Paul Bunge.   

Abstract

Superficial siderosis of the central nervous system is a rare neurological disorder caused by deposits of haemosiderin on subplial brain matter. Characterised by a thin dark layer surrounding the brain stem, cerebellum and cortical fissures on the T2-weighted MRI, symptoms include sensorineural hearing loss and progressive gait ataxia. A specific aetiology for the blood in the subarachnoid space is identified in less than 50% of cases. While identification of a specific vascular defect allows for vascular repair, treatment options are limited for idiopathic superficial siderosis. Recently, a pilot safety study demonstrated promising results using an iron chelator, deferiprone. While this approach is promising, we present a potential serious complication of this therapy-the first report of agranulocytosis in the treatment of superficial siderosis following deferiprone therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925681      PMCID: PMC3762355          DOI: 10.1136/bcr-2013-010099

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Dynamic CT myelography: a technique for localizing high-flow spinal cerebrospinal fluid leaks.

Authors:  Patrick H Luetmer; Bahram Mokri
Journal:  AJNR Am J Neuroradiol       Date:  2003-09       Impact factor: 3.825

2.  Idiopathic superficial siderosis.

Authors:  Thiago Cardoso Vale; Rodrigo Santiago Gomez; Antônio Lúcio Teixeira
Journal:  Arch Neurol       Date:  2011-10

3.  Role of dynamic CT myelography in identifying the etiology of superficial siderosis.

Authors:  Neeraj Kumar; E Paul Lindell; Jessica A Wilden; Dudley H Davis
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

4.  Update on a patient with superficial siderosis on deferiprone.

Authors:  M Levy; R H Llinas
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-10       Impact factor: 3.825

5.  Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.

Authors:  Nicoletta Masera; Luisa Tavecchia; Daniela Valentina Longoni; Oscar Maglia; Andrea Biondi; Giuseppe Masera
Journal:  Blood Transfus       Date:  2011-07-18       Impact factor: 3.443

Review 6.  Iron-chelating therapy for transfusional iron overload.

Authors:  Gary M Brittenham
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 7.  Superficial siderosis should be included in the differential diagnosis of motor neuron disease.

Authors:  Neeraj Kumar; Jeremy L Fogelson; Jonathan M Morris; Mark A Pichelmann
Journal:  Neurologist       Date:  2012-05       Impact factor: 1.398

8.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major.

Authors:  N F Olivieri; G M Brittenham; D Matsui; M Berkovitch; L M Blendis; R G Cameron; R A McClelland; P P Liu; D M Templeton; G Koren
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

9.  Superficial siderosis of the central nervous system - treatment with steroids?

Authors:  R Scheid; S Frisch; M L Schroeter
Journal:  J Clin Pharm Ther       Date:  2009-10       Impact factor: 2.512

10.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

Authors:  Alan R Cohen; Renzo Galanello; Antonio Piga; Vincenzo De Sanctis; Fernando Tricta
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

View more
  5 in total

Review 1.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

2.  Renal clearable nanochelators for iron overload therapy.

Authors:  Homan Kang; Murui Han; Jie Xue; Yoonji Baek; JuOae Chang; Shuang Hu; HaYoung Nam; Min Joo Jo; Georges El Fakhri; Michael P Hutchens; Hak Soo Choi; Jonghan Kim
Journal:  Nat Commun       Date:  2019-11-13       Impact factor: 14.919

3.  Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review.

Authors:  Andreas Flores Martin; Priya Shanmugarajah; Nigel Hoggard; Marios Hadjivassiliou
Journal:  Cerebellum       Date:  2021-01-06       Impact factor: 3.847

4.  Focused Neuro-Otological Review of Superficial Siderosis of the Central Nervous System.

Authors:  Aran Yoo; Jonathan Jou; Jeffrey D Klopfenstein; Jorge C Kattah
Journal:  Front Neurol       Date:  2018-05-28       Impact factor: 4.003

5.  Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis.

Authors:  Y Sammaraiee; G Banerjee; S Farmer; B Hylton; P Cowley; P Eleftheriou; J Porter; D J Werring
Journal:  J Neurol       Date:  2019-10-16       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.